Description: Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally.
Home Page: www.iterumtx.com
ITRM Technical Analysis
Fitzwilliam Court
Dublin,
2
Ireland
Phone:
353 1 669 4820
Officers
| Name | Title |
|---|---|
| Mr. Corey N. Fishman | Pres, CEO & Director |
| Ms. Judith M. Matthews | Chief Financial Officer |
| Dr. Michael W. Dunne M.D. | Strategic Advisor & Director |
| Dr. Sailaja Puttagunta M.D. | Chief Medical Officer |
| Mr. Tom Loughman Ph.D. | Sr. VP of Technical Operations |
| Ms. Louise Barrett | Sr. VP of Legal Affairs & Sec. |
| Dr. Steven I. Aronin M.D. | Sr. VP & Head of Clinical Devel. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 7.5 |
| Price-to-Book MRQ: | 0.4454 |
| Price-to-Sales TTM: | 1349.785 |
| IPO Date: | 2018-05-25 |
| Fiscal Year End: | December |
| Full Time Employees: | 13 |